Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 82 full-time employees. The firm operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The firm stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The firm markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
最新の財務諸表(Form-10K)によると、Cryo-Cell International Incの総資産は$64で、純損失は$0です。
CCELの主要な財務比率は何ですか?
Cryo-Cell International Incの流動比率は0.83、純利益率は0、1株当たり売上高は$3.77です。
Cryo-Cell International Incの収益はセグメントまたは地域別にどのように分けられていますか?
Cryo-Cell International Inc の最大収益セグメントは Umbilical Cord Blood and Cord Tissue Stem Cell Service で、最新の利益発表における収益は 31,551,550 です。地域別に見ると、United States が Cryo-Cell International Inc の主要市場であり、収益は 31,986,106 です。
Cryo-Cell International Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Cryo-Cell International Incの純損失は$0です。